Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 76

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Lung neoplasm malignant

Not recruiting

Study on the Effectiveness of Atezolizumab, Carboplatin, and Nab-Paclitaxel in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Squamous cell carcinoma of the oral cavity+3

Not recruiting

Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Universitaet Des Saarlandes

Respiratory tract infection

Not recruiting

Study on Preventing Respiratory Infections in Elderly Patients Using OM85

Registered drug
Countries:ItalyItaly
  • Participants:65+ years
  • Sponsor:Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon

Lymphangioleiomyomatosis

Not recruiting

Study on the Effects of Loratadine and Rapamycin for Patients with Lymphangioleiomyomatosis (LAM)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Loratadine
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Acasunlimab and Pembrolizumab for Patients with Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Asthma

Not recruiting

Long-term safety study of dexpramipexole tablets in patients with severe eosinophilic asthma who completed EXHALE-2 or EXHALE-3 trials

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexpramipexole Dihydrochloride Monohydrate
  • Sponsor:Areteia Therapeutics Inc.

Small cell lung cancer+1

Not recruiting

Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer recurrent+1

Not recruiting

Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:CLN-081
  • Sponsor:Cullinan Pearl Corp.

Obstructive sleep apnoea syndrome

Not recruiting

Study of sulthiame combined with oral appliance therapy for patients with obstructive sleep apnea who have incomplete response to oral appliance treatment alone

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sultiame
  • Sponsor:Vaestra Goetalandsregionen

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexpramipexole Dihydrochloride Monohydrate
  • Sponsor:Areteia Therapeutics Inc.

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.